You are here
Lancet reports on a new vaccine for Chikungunya fever (MV-CHIK) demonstraing excellent safety, tolerability and good immunogenicity, independent of pre-existing immunity against the vector. MV-CHIK is a promising vaccine for the prevention of chikungunya fever.
THe vaccine was studied in a double-blind, randomised, placebo-controlled study with 263 participants randomized to receive control vaccine (n=34) or MV-CHIK (n=195), or measles prime and MV-CHIK (n=34). The primary endpoint was immunogenicity, defined as the presence of neutralising antibodies against chikungunya virus, at day 56 (28 days after one or two immunisations).
Neutralising antibodies against chikungunya virus were detected in all MV-CHIK treatment groups after one or two immunisations, with mean titres ranging from 12·87 to 174·80 and seroconversion rates ranging from 50·0% to 95·9%.
Adverse events were similar between groups and no serious adverse events related to the vaccine were reported.